Provided by Tiger Trade Technology Pte. Ltd.

Precigen

4.03
+0.04501.13%
Volume:480.26K
Turnover:1.93M
Market Cap:1.42B
PE:-2.81
High:4.08
Open:4.00
Low:3.96
Close:3.98
52wk High:5.47
52wk Low:1.11
Shares:353.82M
Float Shares:205.00M
Volume Ratio:0.54
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4305
EPS(LYR):-0.4715
ROE:-507.72%
ROA:-52.83%
PB:34.02
PE(LYR):-8.54

Loading ...

Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy?

Simply Wall St.
·
Jan 14

Precigen Highlights PAPZIMEOS Launch Success at J.P. Morgan Healthcare Conference

Reuters
·
Jan 12

Director and 10% Owner Randal J. Kirk Reports Sale of Precigen Inc. Common Shares

Reuters
·
Dec 23, 2025

Precigen Director Jeffrey B. Kindler Reports Sale of Common Shares

Reuters
·
Dec 17, 2025

Precigen (PGEN): Valuation in Focus After FDA Approval and Strengthened Cash Position

Simply Wall St.
·
Nov 29, 2025

Can Precigen's (PGEN) Revenue Surge Offset Concerns About Its Expanding Losses?

Simply Wall St.
·
Nov 27, 2025

Director and 10% Owner Randal J. Kirk Reports Disposal of Precigen Inc. Common Shares

Reuters
·
Nov 22, 2025

US High Growth Tech Stocks to Watch in November 2025

Simply Wall St.
·
Nov 17, 2025

Stock Track | Precigen Soars 5.96% as H.C. Wainwright Raises Price Target to $9

Stock Track
·
Nov 14, 2025

Precigen Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 14, 2025

Precigen price target raised to $9 from $8.50 at H.C. Wainwright

TIPRANKS
·
Nov 14, 2025

Precigen reports Q3 EPS ($1.06) vs. (9c) last year

TIPRANKS
·
Nov 14, 2025

Precigen Q3 Loss Widens, Revenue Rises

MT Newswires Live
·
Nov 14, 2025

Biopharmaceutical company Precigen Q3 net loss widens

Reuters
·
Nov 14, 2025

Earnings Flash (PGEN) Precigen Posts Q3 Loss Per Share $1.06, vs. FactSet Est of $0.09 Loss, If Comparable

MT Newswires Live
·
Nov 14, 2025

AquaBounty Technologies Inc. Files Initial Beneficial Ownership Statement for Director Braeden Lichti

Reuters
·
Nov 13, 2025

Precigen Inc. to Report Third Quarter 2025 Financial Results

Reuters
·
Nov 07, 2025

Will Papzimeos FDA Approval and Major Buy Shift Precigen's (PGEN) Investment Narrative?

Simply Wall St.
·
Nov 03, 2025

AquaBounty Technologies Secures $4 Million in Senior Notes Financing at 18% Interest

Reuters
·
Oct 29, 2025

AquaBounty Technologies Reports $1.4 Million Net Loss for Q3 2025

Reuters
·
Oct 28, 2025